Bone Marrow Transplantation News

One-third of insured patients with cancer had out-of-pocket costs that exceeded their expectations, according to study results.

The FDA has granted orphan drug designation for OCU300 to treat ocular graft-versus-host disease, according to a press release from Ocugen.

Maintenance therapy with lenalidomide following autologous hematopoietic stem cell transplantation reduced mortality rates by 25% compared with placebo or observation among patients with newly diagnosed multiple myeloma, according to results of a meta-analysis.

The FDA took action this week on several treatments intended to benefit patients with cancer.

The FDA approved ibrutinib for the treatment of adults with chronic graft-versus-host disease who failed prior systemic therapy.

Patients with advanced cancer who arrived at the ED with delirium had increased rates of hospitalization and ICU admissions, as well as shorter survival rates, according to a study published in The Oncologist.

Patients with advanced cancer had significantly lower survival rates following in-hospital cardiac arrest than those without advanced cancer, according to a retrospective study published in Journal of Oncology Practice.

Four leading national cancer organizations have united in their mission to reduce the number of health disparities in the United States and to ensure all patients, regardless of social demographics and socioeconomic status, benefit from cancer research, according to a joint position statement published in Journal of Clinical Oncology.

Hispanic patients with multiple myeloma in the United States demonstrated the lowest usage rate for autologous hematopoietic stem cell transplantation, according to a report by the Center for International Blood and Marrow Transplant Research.

Both peripheral blood stem cells and unstimulated bone marrow appropriate for haploidentical transplantation when paired with posttransplant cyclophosphamide, study data showed.